The DIA Asia Meeting has been a forum focusing on opportunities and challenges in drug research, development, and regulation in the Asian region since its inception 15 years ago. For the first time to be held in China, DIA Asia 2023 will continue to provide a platform for the industry, regulators, academics and patients to share their knowledge and perspectives of drug development and regulation, discuss emerging trends and issues to help address the challenges arising in drug development and access in Asia. In today’s environment, it is more important than ever to promote patient centricity in drug development, to advance regulatory science to facilitate innovation and to inform regulatory decision-making, and to strengthen collaboration among all stakeholders and across different countries. As the theme of DIA Asia 2023 shows, it is our belief and ambition that greater collaboration in Asian countries will benefit not only the patients in the region, but eventually the patients across the globe.
Program Committee
Program Chair
Ling SU, PhD
Research Fellow, Shenyang Pharmaceutical University Yeehong Business School
DIA Fellow
Program Co-Vice Chairs
Shun JIN, MBA
Head, Regulatory Affairs APMA, Sandoz Asia Pacific Pharmaceutical Pte., Ltd.
Chairman, DIA Advisory Council of Singapore
Yil-Seob LEE,MD, PhD
Professor, Department of Clinical Pharmacology; Director, CHA Global Clinical Trials Center; Vice President, CHA Bundang Medical Center; CHA University
Junko SATO, PhD
Associate Executive Director Pharmaceuticals and Medical Devices Agency (PMDA)
Program Committee
Jianing DI, PhD
Head of China Compound Team Leader Unit (Product Development), Janssen China
Vicky HAN
Senior Director, Policy Group Lead for Asia Pacific, Global Regulatory Affairs, Janssen Pacific
Hyung-Jin JUNG, MD
Medical Director, Janssen, Korea
Sora LEE
Head of Syneos, Korea
Jessica (Jia) LIU, MD
VP, Head of M&A and International Business, Tigermed Consulting Co. Ltd.
Shogo NAKAMORI, R.Ph., MBA
Managing Director, DIA Japan, Korea and Singapore Senior Vice President, DIA Global
Hyo-Young RHIM, MD
Head of Clinical Development, Yuhan
Hironobu SAITO, PhD
Corporate Advisor, Daiichi Sankyo Co., Ltd.
Kum Cheun WONG
Head, Asia Pacific Regulatory & Development Policy, Novartis Asia Pacific Pharmaceuticals Pte. Ltd.
Ping XU, PhD
President, Huilly Pharma Co., Ltd.
Wendy (Xiaojun) YAN, MBA
Senior Vice President Chief Regulatory Officer, BeiGene
Henry YAU, MD, MBA
CEO, The University of Hong Kong Clinical Trials Centre (China) Honorary Assistant Professor Macau University of Science and Technology
I found a good DIA ASIA 2023 at @BagEvent, share it to everyone!
Registration
Preparation Stage
Registration
End of Event
Preparation Stage
Registration
End of Event
Preparation Stage
Registration
End of Event
Choose ticket
Refund Description:
1. The cancellation of the participation fee must be made before August 23. If you need to cancel the conference, you must inform the DIA China Office in writing before the specified date (inclusive), and get a written confirmation from the DIA China Office, and the cancellation will be considered successful 2. For those who have registered and paid for the conference, if they cancel the registration before (inclusive) the specified date, the DIA China Office will handle the refund procedures, and the handling fee is RMB 500 3. For those who have registered and paid for the meeting, if the cancellation procedure is not completed within the time limit, the participation fee will not be refunded 4. The ticket includes coffee breaks, lunch, and meeting materials. Participants should be responsible for accommodation, transportation, and other related expenses related to booking and cancellation
